Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants
Status:
COMPLETED
Trial end date:
2025-06-04
Target enrollment:
Participant gender:
Summary
This study will explore the potential effects of high-fat meal on the plasma pharmacokinetics (PK) of CRS3123 when administered as a single oral dose of 200 mg in healthy adult participants.
Phase:
PHASE1
Details
Lead Sponsor:
Crestone, Inc
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)